Over two-thirds of breast cancers overexpress estrogen receptor (ER), which contributes to breast cancer tumorigenesis and progression.1 Targeted inhibition of ER using selective modulators is considered the optimal treatment for breast cancer patients with ER-positive tumors. The gene discussed is ESR1; the disease is breast cancer.